ALK and neuroblastoma: ALK F1174 mutations arose as acquired resistance mutations in oncogenic ALK fusion proteins during crizotinib and ceritinib treatments (Friboulet et al., 2014; Sasaki et al., 2010), suggesting that F1174L may cause primary resistance to certain ALK inhibitors in neuroblastoma.